USD 12.38
(2.31%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 1.04 Billion USD | 4.54% |
2022 | 1 Billion USD | 7.75% |
2021 | 931.47 Million USD | 13.85% |
2020 | 818.15 Million USD | 5.12% |
2019 | 778.32 Million USD | 4.31% |
2018 | 746.14 Million USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 276.59 Million USD | 11.45% |
2024 Q3 | 285.46 Million USD | 3.21% |
2024 Q1 | 248.17 Million USD | -20.0% |
2023 Q3 | 263.17 Million USD | 3.09% |
2023 FY | 1.04 Billion USD | 4.54% |
2023 Q4 | 310.23 Million USD | 17.88% |
2023 Q1 | 220.59 Million USD | -12.32% |
2023 Q2 | 255.28 Million USD | 15.73% |
2022 Q4 | 251.59 Million USD | 1.16% |
2022 FY | 1 Billion USD | 7.75% |
2022 Q1 | 236.75 Million USD | -1.86% |
2022 Q3 | 248.7 Million USD | -6.73% |
2022 Q2 | 266.63 Million USD | 12.62% |
2021 Q1 | 212.14 Million USD | -2.17% |
2021 FY | 931.47 Million USD | 13.85% |
2021 Q4 | 241.24 Million USD | 6.67% |
2021 Q3 | 226.16 Million USD | -10.22% |
2021 Q2 | 251.91 Million USD | 18.75% |
2020 Q4 | 216.84 Million USD | 8.41% |
2020 Q3 | 200.02 Million USD | -6.13% |
2020 Q2 | 213.08 Million USD | 13.22% |
2020 Q1 | 188.2 Million USD | -2.73% |
2020 FY | 818.15 Million USD | 5.12% |
2019 Q3 | 195.32 Million USD | 0.29% |
2019 FY | 778.32 Million USD | 4.31% |
2019 Q1 | 194.76 Million USD | 0.0% |
2019 Q2 | 194.76 Million USD | 0.0% |
2019 Q4 | 193.48 Million USD | -0.94% |
2018 FY | 746.14 Million USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Aclaris Therapeutics, Inc. | 31.24 Million USD | -3257.829% |
Applied DNA Sciences, Inc. | 13.36 Million USD | -7749.579% |
Aspira Women's Health Inc. | 9.15 Million USD | -11362.617% |
Biodesix, Inc. | 49.08 Million USD | -2037.609% |
BioNexus Gene Lab Corp. | 9.77 Million USD | -10639.012% |
bioAffinity Technologies, Inc. | 2.53 Million USD | -41332.909% |
bioAffinity Technologies, Inc. | 2.53 Million USD | -41332.909% |
Bionano Genomics, Inc. | 36.11 Million USD | -2805.327% |
CareDx, Inc | 280.32 Million USD | -274.313% |
Check-Cap Ltd. | - USD | -Infinity% |
Castle Biosciences, Inc. | 219.78 Million USD | -377.409% |
DarioHealth Corp. | 20.35 Million USD | -5055.7% |
Exact Sciences Corporation | 2.49 Billion USD | 58.025% |
Fulgent Genetics, Inc. | 289.21 Million USD | -262.808% |
Guardant Health, Inc. | 563.94 Million USD | -86.061% |
ICON Public Limited Company | 8.12 Billion USD | 87.078% |
IDEXX Laboratories, Inc. | 3.66 Billion USD | 71.338% |
Illumina, Inc. | 4.5 Billion USD | 76.703% |
Intelligent Bio Solutions Inc. | 3.11 Million USD | -33619.854% |
iSpecimen Inc. | 9.92 Million USD | -10468.781% |
Standard BioTools Inc. | 106.34 Million USD | -886.729% |
MDxHealth SA | 70.19 Million USD | -1394.861% |
23andMe Holding Co. | 219.63 Million USD | -377.735% |
Medpace Holdings, Inc. | 1.88 Billion USD | 44.36% |
Myriad Genetics, Inc. | 678.4 Million USD | -54.671% |
Mainz Biomed B.V. | 895.47 Thousand USD | -117076.171% |
ENDRA Life Sciences Inc. | - USD | -Infinity% |
NeoGenomics, Inc. | 591.64 Million USD | -77.352% |
Neogen Corporation | 924.22 Million USD | -13.532% |
Inotiv, Inc. | 572.42 Million USD | -83.306% |
Natera, Inc. | 1.08 Billion USD | 3.074% |
OPKO Health, Inc. | 863.49 Million USD | -21.516% |
Psychemedics Corporation | 22.09 Million USD | -4648.339% |
Prenetics Global Limited | 21.74 Million USD | -4725.938% |
Prenetics Global Limited | 21.74 Million USD | -4725.938% |
Precipio, Inc. | 15.19 Million USD | -6804.573% |
Personalis, Inc. | 73.48 Million USD | -1327.972% |
RadNet, Inc. | 1.61 Billion USD | 35.094% |
Sera Prognostics, Inc. | 306 Thousand USD | -342804.575% |
Neuronetics, Inc. | 71.34 Million USD | -1370.662% |
Star Equity Holdings, Inc. | 45.78 Million USD | -2191.772% |
Star Equity Holdings, Inc. | 45.78 Million USD | -2191.772% |
Trinity Biotech plc | 56.83 Million USD | -1746.298% |
Twist Bioscience Corporation | 312.97 Million USD | -235.264% |
Exagen Inc. | 52.54 Million USD | -1896.818% |